Appl ying a threshold of greater than 30% inhibition, the hit confirmation rate was determined to be 90%.
The final confirmation of recurrence was determined pathologically or clinically.
The confirmation of neoplastic involvement was determined by histopathological analysis of inguinal and axillaries lymph nodes.
Confirmation of the amplicons was determined by DNA sequencing and the results were analyzed using BLAST software (http://www.ncbi.nlm.nih.gov).nih.gov
Further confirmation of antimicrobial susceptibility was determined by the broth micro-dilution method according to the guidelines of the Clinical and Laboratory Standards Institute (CLSI) [ 15].
Confirmation of the catalyst structure was determined by FTIR, 1H NMR, 13C NMR, 31P NMR and single crystal X-ray diffraction.
Confirmation of tumor cell content was determined microscopically by a cytopathologist.
Statistical significance for inhibitor studies was determined following confirmation of normal distribution, by one-way ANOVA followed by Dunnett's multiple comparisons test.
Confirmation of M. tuberculosis complex was determined by either the BACTEC NAP test (Becton Dickinson) or PCR for IS 6110 [ 17].
Laboratory confirmation for influenza virus infection was determined by reverse transcription PCR, viral culture, direct or indirect fluorescent antibody staining, or rapid antigen testing.
